EU opens first probe into abusive drug patent filings
The European Commission is investigating whether Teva Pharmaceuticals unlawfully delayed the entry of generic drugs to treat multiple sclerosis through patent litigation and a disparaging communications campaign that discredited its competitors.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.